Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol (original) (raw)
The Journal of Sexual Medicine, 2011
Women may use new oral contraceptives (OC) having flexible extended-cycle regimens with a reduced hormone-free interval. Aim. To study the changes of the quality of sexual life in users of the traditional 21/7 or extended-cycle 24/4 OC regimens both containing 3 mg drospirenone and 20 mg ethinyl estradiol. Methods. One hundred fifteen women (age range 18-37 years) were enrolled. Fifty-four women were randomly placed on traditional OC standard regimen, administered for 21 days, followed by a 7-day hormone-free interval (group A); and 61 women were placed on extended-cycle OC regimen covering 24 days of the cycle with a 4-day hormone-free interval (group B).
Fertility and Sterility, 2006
Objective: To evaluate the effects of a low-dose combined oral contraceptive pill (OCP) on peripheral neuroactive steroid concentrations, precursors for neuroactive steroid synthesis, and mood in healthy women desiring contraception. These neuroactive steroids are ␥-aminobutyric acid receptor agonists and are important in the modulation of affect and adaptation to stress. Design: Prospective observational study. Setting: Human ambulatory patient study. Patient(s): Healthy OCP-naive women without current or history of affective disorder. Intervention(s): A 0.020-mg ethinyl E 2 -0.1-mg levonorgestrel containing OCP for 3 months. Main Outcome Measure(s): Serum neuroactive steroids allopregnanolone, allotetrahydrodeoxycorticosterone, and DHEA; neuroactive steroid precursors P and pregnenolone; E 2 ; and mood and anxiety as assessed by the Premenstrual Syndrome Daily Ratings Form, Beck Depression Inventory, Spielberger State-Trait Anxiety Inventory, and Profile of Mood States.
Contraception, 2015
Combined oral contraceptives (COCs) decrease androgen levels, including testosterone (T), which may be associated with sexual dysfunction and mood complaints in some women. We have shown that 'co-administration' of dehydroepiandrosterone (DHEA) to a drospirenone (DRSP)-containing COC restored total T levels to baseline and free T levels by 47%. Here we describe the effects on sexual function, mood and quality of life of such an intervention. This was a randomized, double-blind, placebo-controlled study in 99 healthy COC starters. A COC containing 30mcg ethinylestradiol (EE) and 3mg DRSP was used for three cycles, followed by six cycles of the same COC combined with 50mg/day DHEA or placebo. Subjects completed the Moos Menstrual Distress Questionnaire (MDQ), the McCoy Female Sexuality Questionnaire and the short form of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Safety and tolerability, including effects on skin, were evaluated. The addition of DH...
Further evidence for lack of negative associations between hormonal contraception and mental health
Contraception, 2012
Background: There is limited and inconsistent information concerning the effects of hormonal contraception [oral contraceptives (OCs) and the levonorgestrel-releasing intrauterine system (LNG-IUS)] on mental health. The aim of this work was to further study the association(s) between the use of OCs and the LNG-IUS and psychopathology. Study design: Data concerning adult women who participated in the national FINRISK Study Surveys in Finland in 1997Finland in , 2002Finland in and 2007 were analyzed. The associations between the current use, as well as the duration of use of OCs and the LNG-IUS vs. mood symptoms, psychological and physical symptoms and recent psychiatric diagnoses were tested. Results: A negative association between the current use of OCs and Beck Depression Inventory-13 (BDI-13) score was found. Some other negative associations, all characterized by a small effect size, were detected between current use of OCs and the BDI items feelings of dissatisfaction, feelings of uselessness, irritability, lost interest in people and lost appetite. Additionally, only weak positive associations were found between the duration of OC use and irregular heart rate, insomnia and recent anhedonia. No noteworthy associations emerged between current use of the LNG-IUS, or its duration, and any of the inquired items. Conclusion: The use of hormonal contraception is not associated with negative influence on mental health. Current OC use seems to be associated with better mood, whereas the associations between duration of use of hormonal contraception and mental health effects are not clear.
Effects of the Oral Contraceptive Pill: Psychological and Physiological Variables
2021
Oral contraceptives are one of the most widely used contraceptives in the world. Multiple variations of the oral contraceptive pill (OCP) now exist with limited research examining the psychological impact they may have. The current study examined the psychological and physiological impact of three OCPs. Psychological and physiological variables in participants (N=84) were measured. Results found no significant effect on the psychological variables. An effect was observed in physiological variables; an increase in systolic blood pressure (SBP) on the fourth week of pill cycle in those using Dianette and Ovranette. Similarly, the purpose for which participants were using the OCP had an effect on SBP. This increase was also observed in diastolic blood pressure (DBP) for the group who answered ‘other’. These findings in relation to the week of pill cycle and SBP are particularly interesting and pave the way for further research.
Effects of ethinyl estradiol plus desogestrel on premenstrual symptoms in Iranian women
Acta medica Iranica, 2014
Marvelon®, a combined oral contraceptive, contains 30 μg ethinyl estradiol (EE) and 150 μg desogestrel (DE), and has been shown to be a well-tolerated and effective combination that provides high contraceptive reliability and good cycle control. However, its efficacy has not been yet evaluated among Iranian women. Thus, the study aimed to determine the effect of oral contraceptive pill on treating premenstrual symptoms and on various parameters associated with well-being and health in a sample of Iranian. This clinical trial (before- after) study was performed at the family-planning clinic of the centers under the supervision of Tehran University of Medical Sciences on sixty-one women. The study protocol was approved by the Ethics Committee of Tehran University of Medical Sciences and all participants received a 21/7-day regimen of oral contraceptive containing 150 μg desogestrel (DE) and 30 μg ethinyl estradiol (EE) for six cycles. Efficacy parameters included changes in premenstru...
Oral contraceptives: side effects and depression in adolescent girls B,BB
Objective: The study was undertaken to determine the side effects, including depression, of oral contraceptives (OCs) in adolescent girls. Methods: We conducted a randomized trial of OCs for dysmenorrhea, which assessed side effects and depression. Seventy-six adolescents received an OC (20 Ag of ethinyl estradiol/100 mg of levonorgestrel) or a placebo in a double-blind fashion for 3 months. We ascertained OC side effects using open-ended and closed question formats. Participants self-administered the Center for Epidemiologic Studies Depression Scale (CES-D) to assess depressive symptoms. Results: Fifty-seven participants (77%) reported at least one side effect (median = 2, range = 0–8, interquartile range = 1.0–3.25). The number and the type of side effects reported in the OC group and in the placebo group were similar. Mean exit CES-D scores were comparable between groups [OC group, 14.0 (SD = 9.2); placebo group, 14.4 (SD = 8.1); p = .86]. Conclusion: Adolescents treated with an OC or a placebo experienced similar numbers and types of OC side effects, as well as depressive symptoms.
Psychoneuroendocrinology, 2017
Context: Allopregnanolone is a metabolite from progesterone and a positive modulator of the GABA A receptor. This endogenous steroid may induce negative mood in sensitive women when present in serum levels comparable to the premenstrual phase. Its endogenous isomer, isoallopregnanolone, has been shown to antagonize allopregnanolone effects in experimental animal and human models. Objective: The objective was to test whether inhibition of allopregnanolone by treatment with the GABA A modulating steroid antagonist (GAMSA) Sepranolone (UC1010) during the premenstrual phase could reduce symptoms of the premenstrual dysphoric disorder (PMDD). The pharmacokinetic parameters of UC1010 when given as a subcutaneous injection were measured in healthy women prior to the study in women with PMDD. Design: This was an explorative randomized, double-blind, placebo-controlled study. Setting: Swedish multicentre study with 10 centers. Participants: Participants were 26 healthy women in a pharmacokinetic phase I study part, and 126 women with PMDD in a phase II study part. Diagnosis followed the criteria for PMDD in DSM-5 using Daily Record of Severity of Problems (DRSP) and Endicott's algorithm. Intervention: Subjects were randomized to treatment with UC1010 (10 or 16 mg) subcutaneously every second day during the luteal phase or placebo during one menstrual cycle. Outcome measures: The primary outcome measure was the sum of all 21 items in DRSP (Total DRSP score). Secondary outcomes were Negative mood score i.e. the ratings of the 4 key symptoms in PMDD (anger/irritability, depression, anxiety and lability) and impairment (impact on daily life). Results: 26 healthy women completed the pharmacokinetic phase I study and the dosing in the following trial was adjusted according to the results. 106 of the 126 women completed the phase II study. Within this group, a significant treatment effect with UC1010 compared to placebo was obtained for the Total DRSP score (p = 0.041) and borderline significance (p = 0.051) for the sum of Negative mood score. Nineteen participants however showed symptoms during the follicular phase that might be signs of an underlying other conditions, and 27 participants had not received the medication as intended during the symptomatic phase. Hence, to secure that the significant result described above was not due to chance, a post hoc subgroup analysis was performed, including only women with pure PMDD who completed